An observational study in Urologic Diseases, Urologic Cancer and Infertility, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-10.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Urologic Neoplasms with a site in Italy — 3 open to participants now, 5 under way, 1 of them phase 3. Urologic Neoplasms · Italy.
Among the 14 studies in Urologic Neoplasms with a site in Italy, this one is the only one that started in 2010, is one of 2 observational ones, and was the 13th registered.
157 studies on the registry are indexed under Urologic Neoplasms; 42 are open to participants now.
Browse Urologic Neoplasms studies →3 of the 14 studies in Urologic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Sites in Italy
Ages 18+
Eli Lilly and Company · Sites in Italy, United States, Australia and 11 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 30 Urologic Neoplasms studies recruiting now, 24 (80%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4
First in 2002; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15,000 is above the median of 174 across 33 observational studies indexed under Urologic Neoplasms.
Median enrollment 204 across the 12 interventional studies, 7,750 across the 2 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 14 have an industry lead sponsor. The 10 most frequent:
IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.
IRCCS San Raffaele has 1 study filed under Urologic Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Urologic Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05614739Eli Lilly and CompanyFORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Urologic Neoplasms with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The project aims to collect fresh biological material derived both from surgical resections performed in diseases, neoplastic and otherwise, of urological relevance at the level of the prostate, bladder, kidney, testicle and genitourinary organs, and from peripheral blood or other fluids biological samples such as urine, seminal fluid, buccal mucosa, feces or saliva, when available.
Significant studies have shown the great potential of research based on access to biobanks which has made it possible to conduct studies and obtain important results through retrospective studies carried out on samples collected some time ago. Thanks to the possibility of accessing human biological samples collected and stored in biological banks, great results have been achieved in the medical field. The project aims to collect fresh biological material deriving from surgical resections performed in neoplastic and non-neoplastic pathologies of urological relevance at the level of the prostate, bladder, kidney, testicle and genitourinary organs, both from biological samples of peripheral blood or other fluids such as urine, seminal fluid, buccal mucosa, feces or saliva, when available.
The possibility of obtaining biological samples from the patient at the time of the first visit or the first biopsy and, subsequently, in conjunction with a possible surgical intervention, could ideally give the possibility of studying the disease from its possible onset to the possible intervention, evaluating the evolution and possible association with circulating diagnostic and prognostic markers. The establishment of this collection of research material will allow access to samples of extreme value for the pathophysiological study of the disease, its origin, mechanisms and markers of progression. The data obtained can also be correlated with the patient's clinical history in order to build an overall vision potentially useful in the design of new therapeutic strategies.
157 studies on the registry are indexed under Urologic Neoplasms; 42 are open to participants now.
This study's planned enrollment of 15,000 is above the median of 174 across 33 observational studies indexed under Urologic Neoplasms.
Browse Urologic Neoplasms studies →IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.
Compared within Urologic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urologic Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
People with urological or uro-oncological diseases and infertility
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological samples will be collected from the patient at the time of their access to the Hospital
Biological sample
A biobank is a facility aimed at the collection, management, preservation and distribution of biomaterials and related data for research purposes
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2010 (actual). Primary completion is estimated for Oct 2030, 239 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.